Envoy Medical (COCH) Stock Price, News & Analysis

Company Overview

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Key Stats

• Today's Range: $1.42 to $1.42
• 50-Day Range: $1.26 to $1.53
• 52-Week Range: $1.21 to $5.07
• Volume: 317 shs
• Average Volume: 82,120 shs
• Market Capitalization: $29.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.13
• Consensus Rating: Buy

Envoy Medical Stock Analysis - MarketRank™

Envoy Medical scored higher than 48% of companies evaluated by MarketBeat, and ranked 732nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Envoy Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Envoy Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Envoy Medical are expected to decrease in the coming year, from ($1.21) to ($1.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Envoy Medical is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Envoy Medical is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.95% of the float of Envoy Medical has been sold short.

Short Interest Ratio / Days to Cover

Envoy Medical has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Envoy Medical has recently decreased by 10.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Envoy Medical does not currently pay a dividend.

Dividend Growth

Envoy Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.95% of the float of Envoy Medical has been sold short.

Short Interest Ratio / Days to Cover

Envoy Medical has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Envoy Medical has recently decreased by 10.61%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.88

News Sentiment

Envoy Medical has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Envoy Medical this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Envoy Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Envoy Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

60.50% of the stock of Envoy Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.59% of the stock of Envoy Medical is held by institutions.

COCH Stock Analysis - Frequently Asked Questions

How have COCH shares performed this year?

Envoy Medical's stock was trading at $1.43 at the beginning of the year. Since then, COCH stock has decreased by 2.1% and is now trading at $1.40.
View the best growth stocks for 2025 here.

How were Envoy Medical's earnings last quarter?

Envoy Medical, Inc. (NASDAQ:COCH) posted its quarterly earnings results on Friday, March, 28th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.12. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.07 million.

How do I buy shares of Envoy Medical?

Shares of COCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Envoy Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Envoy Medical investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Tesla (TSLA), XPeng (XPEV), AbCellera Biologics (ABCL), AutoZone (AZO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 3/28/2025
• Today: 4/30/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:COCH
• CIK: 1840877
• Web: www.envoymedical.com
• Phone: 877-900-3277
• Fax: N/A
• Employees: 34
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.13
• High Stock Price Target: $9.25
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +551.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,910,000.00
• Net Margins: -7,607.55%
• Pretax Margin: -7,607.55%
• Return on Equity: N/A
• Return on Assets: -262.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.79
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: $225,000.00
• Price / Sales: 132.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.09) per share
• Price / Book: -15.56

Miscellaneous

• Outstanding Shares: 21,327,000
• Free Float: 7,997,000
• Market Cap: $29.86 million
• Optionable: Not Optionable
• Beta: 2.35